Transplant Matching Molecular Diagnostics Market

   Single User - $2,500
   Site License (one location, 10 users) - $3,500
   Corporate License - $5,000

Published Apr 28, 2017 | 50 Pages | Pub ID: KLI15334860

Transplant Matching Molecular Diagnostics Market

Molecular HLA typing methods allow more precise matching between donor and recipient and is especially critical to bone marrow or HSCT transplant outcomes. Allogenic HSCT transplantation is a relatively high growth procedure area compared to solid organ transplantation and is a leading area of application for molecular HLA typing. Polymorphism in the human major histocompability complex (MHC) or HLA system is exceedingly complex for serological methods and is best captured by directly assaying genetic sequence.  This report, Transplant Matching Molecular Diagnostics Market provides: 

  • United States Molecular Transplant Diagnostics Market, 2016 -2021

  • Europe Molecular Transplant Diagnostics Market, 2016 -2021

  • Japan Molecular Transplant Diagnostics Market, 2016 -2021

  • Rest of World Molecular Transplant Diagnostics Market, 2016 -2021

  • Global Molecular Procedure Volumes, 2016 to 2021 

  • Global Molecular Transplant Diagnostics Market Share by Vendor

The molecular HLA typing market is provided for various regions, and forecasts are made to 2021.   In addition the report discusses trends affecting the molecular transplant matching market.  Successful solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants require histocompatibility between the recipient and donor. Autologous transplantation using hematopoietic cells from the same patient (donor and recipient) is increasingly common and eliminates the need to screen for histocompatibility. However, solid organ transplants and HSCT allografts from another donor requires histocompatibility confirmed by human leukocyte antigen (HLA) testing outside of genetically identical twins.

Proteins encoded by HLA system genes function as unique cell surface markers that regulate immune system recognition of foreign cells such as pathogens and tumor cells. Incompatibility between donor and recipient HLA systems or between donor tissue and recipient antibodies can result in severe complications such as transplant rejection. Testing of donor and recipient HLA systems is essential in cases of allograft between unrelated and even siblings. The most common forms of HLA typing are serological testing of HLA antigens and antibodies and detection of HLA alleles using a variety of molecular diagnostic techniques. Next-generation sequencing (NGS) is expected to develop into a leading option for the determination of HLA alleles.

Company Profiles

As part of its coverage of this market, the report also discusses molecular diagnostics technologies and the state of the molecular diagnostics business.  The following companies are profiled as part of this report:

  • CareDX
  • Illumina
  • Immucor
  • Roche Diagnostics
  • Thermo Fisher Scientific
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.